Press Releases

February 14, 2020

Summary Toggle Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020 Commercial readiness activities in U.S. underway for potential launch of PEDMARK TM , if approved, in the second half of 2020 Solid financial position with $13.7 million and no debt and the option
February 11, 2020

Summary Toggle Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to European Medicines Agency

PEDMARK™ is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children RESEARCH TRIANGLE PARK, N.C. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed its rolling submission